Opc,

Thanks for clearing that up. The wording to me was vague as to whether the cohort of previously Exubera-treated subjects were simply being followed out two additional years for cancer occurence/mortality, with no new Exubera being administered.

Your source raises some good points about the difficulties in interpreting data from this type of study. Hopefully the final data when published will give more clarity around this; until then making interpretations from the abstract alone is pretty speculative IMO.